Cormorant Asset Management »

Abivax SA F shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Abivax SA F (ABVX) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Abivax SA F

Tip: Access up to 7 years of quarterly data

All positions including Abivax SA F held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Abivax SA F by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $23M 2.1M 10.70

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Ambrx Biopharma
Eyepoint Pharmaceuticals Com New (EYPT)
Bridgebio Pharma (BBIO)
Arcellx Common Stock (ACLX)
Rayzebio
Biomea Fusion (BMEA)
Immunovant (IMVT)
Alpine Immune Sciences (ALPN)
Pharvaris N V (PHVS)
Alx Oncology Hldgs (ALXO)
Tarsus Pharmaceuticals (TARS)
Cymabay Therapeutics
Vaxcyte (PCVX)
Crinetics Pharmaceuticals In (CRNX)

View all positions for Cormorant Asset Management

Top funds holding Abivax SA F

Blackstone Group
Cormorant Asset Management
Commodore Capital
Dr. Jeffrey R. Jay, M.D.
Franklin Resources
Nantahala Capital Management
VR Adviser
Samsara BioCapital
Citadel Advisors
Henderson Group
Point72 Asset Management
Rosalind Advisors
Polar Securities
Millennium Management
Kennedy Capital Management

View all funds holding Abivax SA F